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ABSTRACT: The need for systematic follow up of 
medicines for adverse drug reactions once they are 
introduced into general use has been widely recognised 
today. Even in developing countries like India, national 
pharmacovigilance programme has been started for 
monitoring  adverse drug reactions. In its first year this 
program mainly aimed to foster the culture of ADR 
notification among health care professionals. As a part of 
health care team every pharmacist must have knowledge 
about adverse drug reaction monitoring systems and 
pharmacovigilance. 
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“ANYTHING YOU CAN THINK OF, ANYTHING 
YOU CAN SEE AND SOME THINGS YOU DON‟T 
EVEN THINK OF CAN BE DUE TO A DRUG” 
Every occasion when a patient is exposed to a medical 
product, is a unique situation and we can never be certain 
about what might happen. A good example for this is 
thalidomide tragedy in late 1950s and 1960s.Thalidomide 
prescribed as a safe hypnotic to many thousands of 
pregnant women caused severe form of limb abnormality 
known as phocomelia in many of the babies born to those 
women. It was a seminal event that led to the 
development of modern drug regulations aimed to 
identify, confirm and quantify ADRs. An adverse drug 
reaction (ADR) is any undesirable effect of a drug 
beyond anticipated therapeutic effects occurring during 
clinical use (pirmohamed etal1998). Hence every health 
care professional who give advice to patients need to 
know the frequency and magnitude of the risks involved 
in medical treatment along with its beneficial effects. 
Recent epidemiological studies estimated that ADRs are 
fourth to sixth leading cause of death1. It has been 
estimated that approximately 2.9-5% of all hospital 
admission are caused by ADRs and as many as 35% of 
hospitalised patients experience an ADR during their 
hospital stay2 . An incidence of fatal ADRs is 0.23%-
0.4%3. Although many of the ADRs are relatively mild 
and disappear when drug is stopped or dose is reduced, 
others are more serious and last longer. Therefore there is 
a little doubt that ADRs increase not only morbidity and 
mortality but also add to the overall health care cost4-6. 
Pharmacovigilance is the science and activities relating 
to detection, assessment, understanding and prevention of 
adverse effects or any other drug related problems7. 
Pharmacovigilance should however not be limited to the 
reporting of classical adverse effects. It should also be 
concerned with  identification of product defects, 
unexpected insufficient therapeutic effects, intoxications 
and misuse – abuse situations8. According to WHO 
guidelines (2000), functions of pharmacovigilance are 
the detection and study of ADR‟s, measurement of risk 
and effectiveness of drug use, dissemination of this 
information and education. 
Adverse drug reaction (ADR) monitoring involves 
following steps: 
 
I. Identifying adverse drug reaction (ADR) 
II. Assessing causality between drug and suspected 
reaction 
III. Documentation of ADR in patient‟s medical 
records  
IV. Reporting serious ADRs to pharmacovigilance 
centres /ADR regulating authorities 
I. Identifying adverse drug reaction (ADR)  
Several definitions of ADRs exists, including those of 
WHO, FDA, Karch and Lasanga.The WHO definition is 
internationally accepted and most widely used. 
WHO technical report no 498(1972) defines ADR as “A 
response to a drug which is noxious and unintended, and 
which occurs at doses normally used in man for the 
prophylaxis, diagnosis or therapy of disease or for the 
modification of physiological function9. This definition 
excludes therapeutic failures, intentional and accidental 
poisonings and drug abuse. Also this does not include 
adverse events due to errors in drug administration or 
noncompliance (taking more or less of a drug than 
prescribed amount) 3. 
ADRs are mainly identified in the pre-marketing studies 
and in the post-marketing surveillance studies. 
Disadvantages of the pre-marketing studies are that they 
lack sufficient knowledge to extrapolate information 
collected from animal studies directly into risks in 
humans and very few number of subjects (not more than 
4000) are exposed to the new drug prior to the general 
release of product into market. Another major 
disadvantage is that clinical trials can not be done in rare 
group of subjects like children, elderly and pregnant 
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women. For cost reasons clinical trials often have short 
duration which means they can not generate information 
about long term adverse effects. As a consequence of the 
above reasons, only type A adverse reactions are known 
at the time of general marketing of a new drug. So, all 
other types of ADRs can only be identified in post 
marketing surveillance. 
Post marketing surveillance can be done by different 
methods: 
1. Anecdotal reporting10: The majority of the first 
reports of ADR come through anecdotal reports from 
individual doctors when a patient has suffered some 
peculiar effect. Such anecdotal reports need to be 
verified by further studies and these sometimes fail to 
confirm problem. 
2. Intensive monitoring studies11,20: These studies 
provide systematic and detailed collection of data 
from well defined groups of inpatients .The 
surveillance was done by specially trained health care 
professionals who devote their full time efforts 
towards recording all the drugs administered and all 
the events, which might conceivably be drug 
induced. Subsequently, statistical screening for drug-
event association may lead to special studies. Popular 
example for this methodology is Boston collaborative 
drug surveillance program 
Strengths: 
a. Derives incidence rates 
b. Analyses factors which may contribute to reactions 
c. Identifies drug interactions 
d. Generates and tests hypothesis 
F. Under reporting can be minimised 
Weakness: 
a. They need great expense of resources 
b. The relatively short period of observation resulting in 
non identification of delayed reaction 
c. Relatively small proportion of population size 
resulting in non identification of rare reactions 
d. The lack of follow up and outcome information 
3. Spontaneous reporting system (SRS)12: 
It is the principal method used for monitoring the 
safety of marketed drugs. In UK, USA, India and 
Australia, the ADR monitoring programs in use are 
based on spontaneous reporting systems. In this 
system, clinicians are encouraged to report any or all 
reactions that believe may be associated with drug 
use. Usually, attention is focused on new drugs and 
serious ADRs. The rationale for SRS is to generate 
signals of potential drug problems, to identify rare 
ADRs and theoretically to monitor continuously all 
drug used in a variety of real conditions from the 
time they are first marketed.15 
Strengths: 
a. Simple, effective, inexpensive and continuous 
b. The entire population comprising extremes of 
age, people in hospital and community may be 
included 
c. ADRs that are too rare to be demonstrated by 
other methods may be detected 
d. Drugs that are uncommonly used may be 
monitored Weakness: 
a. Under reporting is almost universal 
b. Absence of reliable numerator or denominator 
precludes the provision of quantitative information 
c. Numerous other reporting biases include the novelty 
factor of new drug and the effect of publicity 
d. Reporting rates for each agent or group of agents may 
vary with time. 
e. Clinical information supplied is often limited.   
4. Cohort studies (Prospective studies) 11:  
In these studies, patients taking a particular drug are 
identified and events are then recorded. The 
weakness of this method is relatively small number 
patients likely to be studied, and the lack of suitable 
control group to assess the background incidence of 
any adverse events. Such studies are expensive and it 
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would be difficult to justify and organize such a 
study for every newly marketed drug. 
5. Case control studies (retrospective studies) 10: 
In these studies, patients who present with symptoms 
or an illness that could be due to an adverse drug 
reaction are screened to see if they have taken the 
drug. The prevalence of drug taking in this group is 
then compared with the prevalence in a reference 
population who do not have the symptoms or illness. 
The case control study is thus suitable for 
determining whether the drug causes a given adverse 
event once there is some initial indication that it 
might. However, it is not a method for detecting 
completely new adverse reactions. 
6. Case cohort studies10: 
The case cohort study is a hybrid of prospective 
cohort study and retrospective case control study, 
Patients who present with symptoms or an illness that 
could be due to an adverse drug reaction are screened 
to see if they have taken the drug. The results are 
then compared with the incidence of the symptoms or 
illness in a prospective cohort of patients who are 
taking the drug. 
7. Record linkage10: 
The idea here is to bring together a variety of patient 
records like general practice records of illness events 
and general records of prescriptions. In this way it 
may be possible to match illness events with drugs 
prescribed. A specific example of the use of record 
linkage is the so called prescription event monitoring 
scheme in which all the prescriptions issued by 
selected parishioners for a particular drug are 
obtained from the prescription pricing authority. The 
prescribers are then asked to inform those running 
scheme of any events in the patients taking the drugs. 
This scheme is less expensive and time consuming 
than other surveillance methods 
8. Meta analysis13: 
Meta analysis is a quantitative analysis of 2 or more 
independent studies for the purpose of determining 
an overall effect and of describing reasons for 
variation in study results, is another potential tool for 
identifying ADRs and assessing drug safety. 
9. Use of population statistics14:  
Birth defect registers and cancer registers can be used If 
drug induced event is highly remarkable or very frequent. 
If suspicions are aroused then case control and 
observational cohort studies will be initiated. 




Causality assessment is the method by which the extent 
of relation ship between a drug and a suspected reaction 
is established. There are three approaches to asses‟ 
causality. These include    
a) Opinion of an individual expert 
b) Opinion of a panel of experts 
c) Formal algorithms 
In the first approach, an individual who is an expert in 
the area of ADRs would evaluate the case. In the process 
of evaluation, he or she may consider and critically 
evaluate all the data obtained to assess whether the drug 
has caused the particular reaction. A panel of experts 
adopts a similar procedure to arrive at a collective 
opinion. Using formal algorithms, collected data is 
subjected and critically assessed by using one or more 
standard algorithms. 
Some of the important algorithms used are Naranjo, 
WHO, European ABO system, Kramer, Bayesian, Karch 
and lasanga and French imputation method. There is no 
gold standard for causality assessment. The 
categorisation of causal relationship between a drug and 
suspected adverse reactions varies with the scale adopted.  
WHO scale categorises the causality relationship into 
certain, probable, possible, unassessible/unclassifiable, 
unlikely, conditional /unclassifiable. The Naranjo‟s scale 
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categorises the reaction as definite, probable, possible or 
unlikely.  
In general the following four different basic points can be 
considered in attributing a clinical adverse event to the 
drug. 
1. Temporal time relationship between 
suspected reaction and drug. 
2. Dechallenge (cessation of drug) 
3. Rechallenge (re introducing drugs) 
4. Likelihood of other possible causes 
         
   
Table 1: Causality assessment strengths and limitations 
       What causality assessment can do            What causality assessment can not do 
 Decreases disagreement between 
assessors 
 Classify relationship likelihood 
 Mark individual case reports 
 Education /improvement of scientific 
assessment 
 Exact quantification measurement of 
relationship likelihood 
 Distinguish valid from invalid cases 
 Prove the connection between drug and 
event 
 Quantify the contribution of a drug to the 
development of an adverse event 
 Change uncertainty into certainty 
 
III. Documentation of ADRs in patient’s medical 
records 
This aids as reference for alerting clinicians and other 
health care professionals to the possibility of a particular 
drug causing suspected reaction. 
IV. Reporting serious ADRs to pharmacovigilance 
centers / ADR regulating authorities 
According to FDA, a serious reaction is classified as one 
which is fatal, life threatening, prolonging 
hospitalisation, causing a significant persistent disability, 
resulting in a congenital anomaly and requiring 
intervention to prevent permanent damage or resulting in 
death16.  
Hatwig SC, Seigel J and Schneider PJ categorised ADRs 
into seven levels as per their severity. Level 1&2 fall 
under mild category whereas level 3& 4 under moderate 
and level 5, 6&7 fall under severe category. 
Karch and Lasanga classify severity into minor, 
moderate, severe and lethal. In minor severity, there is no 
need of antidote, therapy or prolongation of 
hospitalisation. To classify as moderate severity, a 
change in drug therapy, specific treatment or an increase 
in hospitalization by at least one day is required. Severe 
class includes all potentially life threatening reactions 
causing permanent damage or requiring intensive 
medical care. Lethal reactions are the one which directly 
or indirectly contributes to death of the patient.  
Different ADR regulatory authorities are - Committee on 
safety of medicine (CSM), Adverse drug reaction 
advisory committee (ADRAC)17, MEDWATCH, 
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Vaccine Adverse Event Reporting System18. WHO-UMC 
international database maintains all the data of ADRs. 
In India, national pharmacovigilance programme19 was 
officially inaugurated on 23rd November 2004. It has one 
national pharmacovigilance center located at CDSCO in  
Delhi, two zonal, five regional and twenty four peripheral 
centers. National pharmcovigillance center 
communicates all the reported ADR data to WHO – 
UMC international database. 
 
CONCLUSION:  India has more than half a million 
qualified doctors and 15,000 hospitals having bed 
strength of 6, 24,000. It is the fourth largest producer of 
pharmaceuticals in the world. It is emerging as important 
clinical trial hub in the world. Many new drugs are being 
introduced every year and so every health care 
professional must have knowledge about importance of 
ADR monitoring and pharmacovigilance. Every health 
care professional should see it as a part of his/her 
professional duty keeping in mind about Hippocrates 
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